查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1182201

強直性脊柱炎全球市場規模研究和預測：按藥物類別（NSAIDs、TNF 抑製劑、其他）、分銷渠道（醫院藥房、零售藥房、在線藥房）、區域分析，2022-2029 年

Global Ankylosing Spondylitis Market Size study & Forecast, by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球強直性脊柱炎市場價值約為 53.8 億美元，預計在 2022-2029 年預測期內將以超過 4.6% 的健康增長率增長。

強直性脊柱炎是一種炎症性疾病，脊柱骨（椎骨）融合在一起。 這種融合會影響脊柱的柔韌性並導致不良姿勢。 如果肋骨受到影響，深呼吸可能會很困難。 強直性脊柱炎的症狀包括背痛、臀部疼痛、肩膀僵硬、頸部疼痛、韌帶和肌腱疼痛、疲勞和盜汗。 關節炎患病率上升、強直性脊柱炎發病率上升以及主要市場參與者的戰略舉措是加速市場增長的主要因素。

關節炎患病率上升促進了全球強直性脊柱炎市場的增長。 例如，關節炎基金會估計——截至 2019 年，全世界有超過 5400 萬成年人和大約 300,000 名兒童患有關節炎或其他類型的風濕病。 此外，強直性脊柱炎發病率的增加也推動了這一市場的增長。 例如，根據美國脊柱炎協會的數據，截至 2020 年，美國有超過 170 萬成年人患有 AS。 同時，約有 320 萬人患有中軸型脊柱關節炎。 此外，越來越多的骨科醫院和診斷中心，以及新興國家醫療基礎設施發展的改善，也有望在預測期內為市場創造良好的增長前景。 然而，與強直性脊柱炎相關的高昂治療費用將阻礙整個 2022-2029 年預測期內的市場增長。

強直性脊柱炎全球市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於強直性脊柱炎患病率上升和區域醫療基礎設施的增長等因素，北美已成為市場份額的主要地區。 另一方面，由於老年人口增加和醫療基礎設施發展等因素，預計亞太地區在預測期內將以最高複合年增長率增長。

這項研究的目的是揭示近年來各個細分市場和國家/地區的市場規模，並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家工業的定性和定量方面。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含供利益相關者投資的微觀市場潛在機會，以及對主要參與者的競爭格局和產品供應的深入分析。

按藥物類別

非甾體抗炎藥

腫瘤壞死因子抑製劑

雜項

按銷售渠道

醫院藥房

零售商

在線藥店

內容

第 1 章執行摘要

  • 市場概況
  • 2019 年至 2029 年按細分市場估算和預測全球市場
    • 強直性脊柱炎市場：按地區劃分，2019-2029 年
    • 強直性脊柱炎市場（按藥物類別）：2019-2029
    • 強直性脊柱炎市場：按分銷渠道，2019-2029 年
  • 主要趨勢
  • 調查方法介紹
  • 調查先決條件

第 2 章強直性脊柱炎全球市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第 3 章強直性脊柱炎的全球市場動態

  • 強直性脊柱炎市場影響分析 (2019-2029)
    • 市場驅動因素
      • 關節炎的患病率增加。
      • 強直性脊柱炎患病率增加
      • 主要市場參與者的戰略舉措
    • 市場挑戰
      • 強直性脊柱炎的高昂治療費用
    • 市場機會
      • 骨科醫院和診斷中心的數量增加
      • 發展中地區的醫療保健基礎設施有所增加

第 4 章強直性脊柱炎全球市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 投資招聘模式
  • 分析師的結論和建議
  • 頂級投資機會
  • 關鍵成功策略

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球強直性脊柱炎市場：按藥物類別分類

  • 市場概況
  • 全球強直性脊柱炎市場：按藥物類別、性能-潛力分析
  • 2019-2029 年按藥物類別劃分的全球強直性脊柱炎市場、估計和預測
  • 強直性脊柱炎市場細分分析
    • 非甾體抗炎藥
    • 腫瘤壞死因子抑製劑
    • 其他

第 7 章：全球強直性脊柱炎市場：按分銷渠道

  • 市場概況
  • 全球強直性脊柱炎市場：按分銷渠道進行的性能潛力分析
  • 全球強直性脊柱炎市場：按分銷渠道估算和預測 (2019-2029)
  • 強直性脊柱炎市場細分分析
    • 醫院藥房
    • 零售藥房
    • 在線藥店

第 8 章全球強直性脊柱炎市場：區域分析

  • 強直性脊柱炎市場：按地區劃分的市場概況
  • 北美
    • 美國
      • 2019-2029 年按藥物類別的估計和預測
      • 2019-2029 年各分銷渠道的估計和預測
    • 加拿大
  • 歐洲強直性脊柱炎市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區強直性脊柱炎市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲強直性脊柱炎市場概況
    • 巴西
    • 墨西哥
  • 世界其他地區

第 9 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • AbbVie Inc.
      • 主要信息
      • 概覽
      • 財務信息（取決於數據可用性）
      • 產品概述
      • 近期趨勢
    • Amgen, Inc,
    • Eli Lilly and Company
    • Gilead Sciences Inc
    • Janssen Pharmaceuticals
    • Merck & Co. Inc
    • Novartis AG,
    • Pfizer, Inc
    • Reliance Life Sciences Pvt. Ltd
    • UCB, Inc.,

第 10 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查屬性
  • 調查先決條件

Global Ankylosing Spondylitis Market is valued at approximately USD 5.38 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.6% over the forecast period 2022-2029. Ankylosing Spondylitis refers to an inflammatory disease that causes the bones in the spine (vertebrae) to fuse. This fusing affects the spine's flexibility and can result in poor posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing Spondylitis symptoms include pain in the lower back, hips, and buttocks, stiffness in the lower back, hips, and buttocks. neck pain, ligament and tendon pain, tiredness, and night sweats among others. The growing prevalence of Arthritis and rising incidences of Ankylosing Spondylitis as well as strategic initiatives from leading market players are key factors accelerating the market growth.

The rising prevalence of Arthritis is contributing to the growth of the Global Ankylosing Spondylitis Market. For instance, according to Arthritis Foundation estimates - as of 2019, globally more than 54 million adults and approximately 300,000 children are affected by arthritis or another type of rheumatic disease. Moreover, increasing incidences of Ankylosing Spondylitis are also fueling up the growth of the Market. For instance, as per Spondylitis Association of America - as of 2020 more than 1.7 million adults in the U.S. are affected by AS. Whereas, around 3.2 million have a form of axial spondyloarthritis. Also, the rising number of orthopedic hospitals and diagnostic centers and growing healthcare infrastructure in developing regions would create lucrative growth prospects for the market over the forecast period. However, the high treatment cost associated with Ankylosing Spondylitis stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Ankylosing Spondylitis Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as the rising prevalence of Ankylosing Spondylitis as well as growing healthcare infrastructure in the region. Whereas the Asia Pacific is expected to grow with the highest CAGRduring the forecast period, owing to factors such as rising geriatric individuals as well as growing healthcare infrastructure in the region.

Major market players included in this report are:

AbbVie Inc.

Amgen, Inc,

Eli Lilly and Company

Gilead Sciences Inc.

Janssen Pharmaceuticals

Merck & Co. Inc

Novartis AG,

Pfizer, Inc

Reliance Life Sciences Pvt. Ltd

UCB, Inc.,

Recent Developments in the Market:

  • In December 2021, US-based Pfizer has received FDA approval for its Tofacitinib. Tofacitinib is the first Janus kinase (JAK) inhibitor, or JAKi, that received approval for treatment of adults with active AS.

Global Ankylosing Spondylitis Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Class, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class

NSAIDs

TNF Inhibitors

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Ankylosing Spondylitis Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Ankylosing Spondylitis Market, by Drug Class, 2019-2029 (USD Billion)
    • 1.2.3. Ankylosing Spondylitis Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Ankylosing Spondylitis Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Ankylosing Spondylitis Market Dynamics

  • 3.1. Ankylosing Spondylitis Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of Arthritis.
      • 3.1.1.2. Growing incidences of Ankylosing Spondylitis
      • 3.1.1.3. Strategic initiatives from leading market players
    • 3.1.2. Market Challenges
      • 3.1.2.1. High treatment cost of Ankylosing Spondylitis
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing number of orthopedic hospitals and diagnostic centers
      • 3.1.3.2. Rising healthcare infrastructure in developing regions.

Chapter 4. Global Ankylosing Spondylitis Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Ankylosing Spondylitis Market, by Drug Class

  • 6.1. Market Snapshot
  • 6.2. Global Ankylosing Spondylitis Market by Drug Class, Performance - Potential Analysis
  • 6.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 6.4. Ankylosing Spondylitis Market, Sub Segment Analysis
    • 6.4.1. NSAIDs
    • 6.4.2. TNF inhibitors
    • 6.4.3. Others

Chapter 7. Global Ankylosing Spondylitis Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Ankylosing Spondylitis Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Ankylosing Spondylitis Market, Sub Segment Analysis
    • 7.4.1. Hospital pharmacy
    • 7.4.2. Retail pharmacy
    • 7.4.3. Online pharmacy

Chapter 8. Global Ankylosing Spondylitis Market, Regional Analysis

  • 8.1. Ankylosing Spondylitis Market, Regional Market Snapshot
  • 8.2. North America Ankylosing Spondylitis Market
    • 8.2.1. U.S. Ankylosing Spondylitis Market
      • 8.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Ankylosing Spondylitis Market
  • 8.3. Europe Ankylosing Spondylitis Market Snapshot
    • 8.3.1. U.K. Ankylosing Spondylitis Market
    • 8.3.2. Germany Ankylosing Spondylitis Market
    • 8.3.3. France Ankylosing Spondylitis Market
    • 8.3.4. Spain Ankylosing Spondylitis Market
    • 8.3.5. Italy Ankylosing Spondylitis Market
    • 8.3.6. Rest of Europe Ankylosing Spondylitis Market
  • 8.4. Asia-Pacific Ankylosing Spondylitis Market Snapshot
    • 8.4.1. China Ankylosing Spondylitis Market
    • 8.4.2. India Ankylosing Spondylitis Market
    • 8.4.3. Japan Ankylosing Spondylitis Market
    • 8.4.4. Australia Ankylosing Spondylitis Market
    • 8.4.5. South Korea Ankylosing Spondylitis Market
    • 8.4.6. Rest of Asia Pacific Ankylosing Spondylitis Market
  • 8.5. Latin America Ankylosing Spondylitis Market Snapshot
    • 8.5.1. Brazil Ankylosing Spondylitis Market
    • 8.5.2. Mexico Ankylosing Spondylitis Market
  • 8.6. Rest of The World Ankylosing Spondylitis Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. AbbVie Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Amgen, Inc,
    • 9.2.3. Eli Lilly and Company
    • 9.2.4. Gilead Sciences Inc
    • 9.2.5. Janssen Pharmaceuticals
    • 9.2.6. Merck & Co. Inc
    • 9.2.7. Novartis AG,
    • 9.2.8. Pfizer, Inc
    • 9.2.9. Reliance Life Sciences Pvt. Ltd
    • 9.2.10. UCB, Inc.,

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Ankylosing Spondylitis Market, report scope
  • TABLE 2. Global Ankylosing Spondylitis Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Ankylosing Spondylitis Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
  • TABLE 4. Global Ankylosing Spondylitis Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 5. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Ankylosing Spondylitis Market
  • TABLE 70. List of primary sources, used in the study of global Ankylosing Spondylitis Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Ankylosing Spondylitis Market, research methodology
  • FIG 2. Global Ankylosing Spondylitis Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Ankylosing Spondylitis Market, key trends 2021
  • FIG 5. Global Ankylosing Spondylitis Market, growth prospects 2022-2029
  • FIG 6. Global Ankylosing Spondylitis Market, porters 5 force model
  • FIG 7. Global Ankylosing Spondylitis Market, pest analysis
  • FIG 8. Global Ankylosing Spondylitis Market, value chain analysis
  • FIG 9. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Ankylosing Spondylitis Market, regional snapshot 2019 & 2029
  • FIG 15. North America Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Ankylosing Spondylitis Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable